Role of HMGB1 signaling in the inflammatory process in diabetic retinopathy
- 1 June 2020
- journal article
- review article
- Published by Elsevier in Cellular Signalling
- Vol. 73, 109687
Abstract
No abstract availableKeywords
Funding Information
- National Eye Institute
- Research to Prevent Blindness
This publication has 66 references indexed in Scilit:
- Knockout of toll-like receptor-4 attenuates the pro-inflammatory state of diabetesCytokine, 2011
- Inflammation in diabetic retinopathyProgress in Retinal and Eye Research, 2011
- Increased Toll-Like Receptor (TLR) Activation and TLR Ligands in Recently Diagnosed Type 2 Diabetic SubjectsDiabetes Care, 2010
- Phase 2 trial of eritoran tetrasodium (E5564), a Toll-like receptor 4 antagonist, in patients with severe sepsis*Critical Care Medicine, 2010
- Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1)Angiogenesis, 2008
- Olmesartan Blocks Inflammatory Reactions in Endothelial Cells Evoked by Advanced Glycation End Products by Suppressing Generation of Reactive Oxygen SpeciesOphthalmic Research, 2007
- Contributions of Inflammatory Processes to the Development of the Early Stages of Diabetic RetinopathyJournal of Diabetes Research, 2007
- Upregulation of RAGE and its ligands in proliferative retinal diseaseExperimental Eye Research, 2006
- Interleukin-1 antagonizes morphine analgesia and underlies morphine tolerancePain, 2005
- A central role for inflammation in the pathogenesis of diabetic retinopathyThe FASEB Journal, 2004